Quantum BioPharma Ltd. (QNTM) Earnings History
Annual and quarterly earnings data from 2015 to 2025
Loading earnings history...
QNTM EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
QNTM Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export QNTM earnings history in CSV or JSON format
Free sign-in required to download data
Quantum BioPharma Ltd. (QNTM) Earnings Overview
As of May 8, 2026, Quantum BioPharma Ltd. (QNTM) reported trailing twelve-month net income of -$26M, reflecting +35.1% year-over-year growth. The company earned $-6.74 per diluted share over the past four quarters.
Looking at the long-term picture, QNTM's historical earnings data spans multiple years. The company achieved its highest annual net income of -$29,629 in fiscal 2016.
Quantum BioPharma Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SAVA (-$106M net income), ANVS (-$29M net income), NRXP (-$38M net income, -2336.5% margin), QNTM has comparable earnings metrics. Compare QNTM vs SAVA →
QNTM Earnings vs Peers
Earnings metrics vs comparable public companies
QNTM Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$27M | -87.5% | -$16M | $-8.11 | - | - |
| 2024 | -$14M | +20.7% | -$16M | $-12.49 | - | - |
| 2023 | -$18M | +24.2% | -$24M | $-29.39 | - | - |
| 2022 | -$24M | +33.1% | -$27M | $-39.62 | - | - |
| 2021 | -$35M | -11.0% | -$34M | $-65.63 | - | - |
| 2020 | -$32M | +18.7% | -$31M | $-171.62 | - | - |
| 2019 | -$39M | -134.7% | -$22M | $-360.45 | - | - |
| 2018 | -$17M | -494.9% | $0 | $-183.54 | - | - |
| 2017 | -$3M | -9359.6% | -$3M | $-27.75 | -13586.0% | -13586.0% |
| 2016 | $-29,629 | +9.7% | $0 | $-0.29 | - | - |
See QNTM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs QNTM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare QNTM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonQNTM — Frequently Asked Questions
Quick answers to the most common questions about buying QNTM stock.
Is QNTM growing earnings?
QNTM EPS is $-6.74, with earnings growth accelerating to +35.1%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-26M.
What are QNTM's profit margins?
Quantum BioPharma Ltd. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are QNTM's earnings?
QNTM earnings data spans 2015-2025. The accelerating earnings trend is +35.1% YoY. Historical data enables comparison across business cycles.